Biotech IP
The molecule wars get the attention, but the formulation patents — how the peptide is stabilized and delivered — are where the practical freedom-to-operate question lives.
Biotech IP
An ADC is an antibody, a toxin, and the chemistry that joins them. The patents almost always turn on that joining chemistry — the linker is where the invention lives.
Biotech IP
Vertex's cystic-fibrosis franchise is protected by waves of patents filed over a decade. The layering, not any single grant, is what holds the exclusivity.
Biotech IP
Therapeutic antibodies are the biggest drug class by IP volume. Mapping the C07K assignee record shows a Genentech-anchored field with a long, crowded tail.
Biotech IP
The mRNA molecule gets the headlines, but the patents that decide who can ship are about the fat droplet that carries it. Here is who holds the LNP delivery record.
Biotech IP
The foundational CRISPR estate is famously contested. Mapping the assignees behind the C12N grants shows the fight is institutional, not corporate, at the root.
Biotech IP
The metabolic-drug field moved from GLP-1 mono-agonists to GIP/GLP-1 duals to GLP-1/GIP/glucagon triples. Each step is a new claimable species — and a new scope fight.
Biotech IP
Eylea and Lucentis live in the anti-VEGF field, but the patents that define it range from broad genus claims to narrow humanized species. The scope gap is the whole fight.
Biotech IP
A pile of patents is not the same as a defensible one. Auditing Novo's GLP-1 holdings by claim type separates the genuine barrier from the defensive clutter.
Biotech IP
Tirzepatide is a dual-receptor drug, and Lilly's method patents claim the use, not just the molecule. The distinction decides the franchise's defensibility.
Biotech IP
Base editing rewrites a single DNA letter without cutting both strands. The patents claim a fusion — and the deaminase half is where the scope is decided.
Biotech IP
Off-target editing is CRISPR's central liability. A General Hospital patent claims a counterintuitive fix — make the guide RNA shorter — and the limitation is precise.